{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:51:24Z","timestamp":1791521484192,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["114TMU-SHH-29"],"award-info":[{"award-number":["114TMU-SHH-29"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["TMU112-AE1-B08"],"award-info":[{"award-number":["TMU112-AE1-B08"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST110-2628-B-002-036"],"award-info":[{"award-number":["MOST110-2628-B-002-036"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2311-B-038-006-MY3"],"award-info":[{"award-number":["NSTC 113-2311-B-038-006-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC113-2314-B-038-021"],"award-info":[{"award-number":["NSTC113-2314-B-038-021"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-038-089-MY3"],"award-info":[{"award-number":["NSTC 114-2314-B-038-089-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.metabol.2026.156748","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:22:26Z","timestamp":1787034146000},"page":"156748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mesenchymal stem cell therapy for diabetes: clinical evidence, emerging strategies, and future perspectives"],"prefix":"10.1016","volume":"184","author":[{"given":"Han-Ying","family":"Jhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156748_bb0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2026.156748_bb0010","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/sctm.21-0021","article-title":"Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells","volume":"10","author":"Wang","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.metabol.2026.156748_bb0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12929-016-0289-5","article-title":"Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials","volume":"23","author":"Wang","year":"2016","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.metabol.2026.156748_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00236","article-title":"Immunomodulatory effect of adipose-derived stem cells: the cutting edge of clinical application","volume":"8","author":"Ceccarelli","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.metabol.2026.156748_bb0025","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1111\/febs.16438","article-title":"Clinical implications of differential functional capacity between tissue-specific human mesenchymal stromal\/stem cells","volume":"290","author":"Yen","year":"2023","journal-title":"FEBS J"},{"key":"10.1016\/j.metabol.2026.156748_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13287-021-02222-y","article-title":"Human umbilical cord-derived mesenchymal stem\/stromal cells: a promising candidate for the development of advanced therapy medicinal products","volume":"12","author":"Mebarki","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0035","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156748_bb0040","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2026.156748_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2026.156748_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156748_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"npj Regener Med"},{"key":"10.1016\/j.metabol.2026.156748_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2026.123998","article-title":"3D culture reveals dual role of ICAM-1 in mediating tissue-specific human MSC spheroid formation & enhanced immunomodulation","volume":"330","author":"Wang","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.metabol.2026.156748_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107716","article-title":"Lack of IFN-gamma response of human uterine myometrium-derived MSCs significantly improve multiple IBD parameters compared to bone marrow MSCs: implications for anti-TNFalpha-refractory patients","volume":"215","author":"Wang","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2026.156748_bb0070","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.metabol.2026.156748_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2026.156748_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/thoraxjnl-2021-217928","article-title":"Placental mesenchymal stem cells boost M2 alveolar over M1 bone marrow macrophages via IL-1beta in Klebsiella-mediated acute respiratory distress syndrome","volume":"78","author":"Wang","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.metabol.2026.156748_bb0085","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.822","article-title":"Adipose tissue stem cells in regenerative medicine","volume":"12","author":"Miana","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.metabol.2026.156748_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156748_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00993","article-title":"Allogenic adipose tissue-derived stromal\/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: a 3-month follow-up pilot study","volume":"11","author":"Araujo","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2026.156748_bb0100","first-page":"342","article-title":"Adipose tissue-derived stromal\/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients","volume":"65","author":"Dantas","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.metabol.2026.156748_bb0105","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00125-023-05934-3","article-title":"Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I\/II randomised double-blind placebo-controlled trial","volume":"66","author":"Carlsson","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156748_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/dc15-0171","article-title":"Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion","volume":"39","author":"Cai","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2026.156748_bb0115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jcyt.2021.09.015","article-title":"Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up","volume":"24","author":"Wu","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.metabol.2026.156748_bb0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13287-022-02941-w","article-title":"Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial","volume":"13","author":"Izadi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13287-020-01610-0","article-title":"Mesenchymal stem cell-derived exosomes protect beta cells against hypoxia-induced apoptosis via miR-21 by alleviating ER stress and inhibiting p38 MAPK phosphorylation","volume":"11","author":"Chen","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732549","article-title":"Human Wharton\u2019s jelly-derived mesenchymal stromal cells primed by tumor necrosis factor-alpha and interferon-gamma modulate the innate and adaptive immune cells of type 1 diabetic patients","volume":"12","author":"Mrahleh","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2026.156748_bb0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s13577-023-00868-9","article-title":"Human umbilical cord mesenchymal stem cell-derived TGFBI attenuates streptozotocin-induced type 1 diabetes mellitus by inhibiting T-cell proliferation","volume":"36","author":"Wu","year":"2023","journal-title":"Hum Cell"},{"key":"10.1016\/j.metabol.2026.156748_bb0140","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.7754\/Clin.Lab.2014.140305","article-title":"Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus","volume":"60","author":"Kong","year":"2014","journal-title":"Clin Lab"},{"key":"10.1016\/j.metabol.2026.156748_bb0145","first-page":"349","article-title":"The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and beta cell function in type 2 diabetes mellitus","volume":"55","author":"Chen","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.metabol.2026.156748_bb0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13287-022-02848-6","article-title":"Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial","volume":"13","author":"Zang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13287-024-03907-w","article-title":"Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up","volume":"15","author":"Wu","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13287-017-0668-1","article-title":"Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats","volume":"8","author":"Sun","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0165","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1021\/acsnano.7b07643","article-title":"Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction","volume":"12","author":"Sun","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.metabol.2026.156748_bb0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4093\/dmj.2019.0191","article-title":"Umbilical cord-mesenchymal stem cell-conditioned medium improves insulin resistance in C2C12 cell","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2026.156748_bb0175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2337\/db18-0699","article-title":"Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers","volume":"68","author":"Moon","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156748_bb0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s13063-021-05430-2","volume":"22","author":"Soria-Juan","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.metabol.2026.156748_bb0185","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1742-1241.2011.02886.x","article-title":"Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients","volume":"66","author":"Kirana","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2026.156748_bb0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13287-023-03427-z","article-title":"A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells","volume":"14","author":"Arango-Rodriguez","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0195","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s13287-025-04690-y","article-title":"The transforming role of Wharton\u2019s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial","volume":"16","author":"Kishta","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13287-018-0854-9","article-title":"Efficacy and long-term longitudinal follow-up of bone marrow mesenchymal cell transplantation therapy in a diabetic patient with recurrent lower limb bullosis diabeticorum","volume":"9","author":"Chen","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/0963689719835177","article-title":"Long-term outcomes of BMMSC compared with BMMNC for treatment of critical limb ischemia and foot ulcer in patients with diabetes","volume":"28","author":"Lu","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.metabol.2026.156748_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cells11203229","article-title":"Exosomes from adipose stem cells promote diabetic wound healing through the eHSP90\/LRP1\/AKT axis","volume":"11","author":"Ren","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2026.156748_bb0215","article-title":"Exosomes derived from adipose mesenchymal stem cells promote diabetic chronic wound healing through SIRT3\/SOD2","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.metabol.2026.156748_bb0220","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1021\/acsnano.3c09814","article-title":"A dual role of mesenchymal stem cell derived small extracellular vesicles on TRPC6 protein and mitochondria to promote diabetic wound healing","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.metabol.2026.156748_bb0225","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s42003-024-07367-z","article-title":"MSC-derived exosomal circMYO9B accelerates diabetic wound healing by promoting angiogenesis through the hnRNPU\/CBL\/KDM1A\/VEGFA axis","volume":"7","author":"Wang","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.metabol.2026.156748_bb0230","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.metabol.2026.156748_bb0235","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12951-024-02613-2","article-title":"Single-cell RNA transcriptomic reveal the mechanism of MSC derived small extracellular vesicles against DKD fibrosis","volume":"22","author":"Ji","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.metabol.2026.156748_bb0240","article-title":"Dual-targeted engineered mesenchymal stem cell-derived extracellular vesicles delivering Nedd4 attenuate renal fibrosis in diabetic kidney disease","volume":"38","author":"Ji","year":"2026","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.metabol.2026.156748_bb0245","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13287-025-04265-x","article-title":"Extracellular vesicles derived from mesenchymal stem cells alleviate renal fibrosis via the miR-99b-5p\/mTOR\/autophagy axis in diabetic kidney disease","volume":"16","author":"Li","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0250","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1159\/000517364","article-title":"Safety and efficacy of 2 intracavernous injections of allogeneic Wharton\u2019s jelly-derived mesenchymal stem cells in diabetic patients with erectile dysfunction: phase 1\/2 clinical trial","volume":"105","author":"Al Demour","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.metabol.2026.156748_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sctm.17-0139","article-title":"Autologous mesenchymal stem cell and islet Cotransplantation: safety and efficacy","volume":"7","author":"Wang","year":"2018","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.metabol.2026.156748_bb0260","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13287-022-02974-1","article-title":"Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes","volume":"13","author":"Zhang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0265","doi-asserted-by":"crossref","DOI":"10.1111\/and.14440","article-title":"A study of diabetes-induced erectile dysfunction treated with human umbilical cord mesenchymal stem cells","volume":"54","author":"Wang","year":"2022","journal-title":"Andrologia"},{"key":"10.1016\/j.metabol.2026.156748_bb0270","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00125-019-05043-0","article-title":"Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes","volume":"63","author":"Fan","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156748_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/stmcls\/sxad078","article-title":"MSC-derived small extracellular vesicles alleviate diabetic retinopathy by delivering miR-22-3p to inhibit NLRP3 Inflammasome activation","volume":"42","author":"Chen","year":"2024","journal-title":"Stem Cells"},{"key":"10.1016\/j.metabol.2026.156748_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110586","article-title":"MSC-derived small extracellular vesicles attenuate diabetic retinopathy through miR-29a-3p regulated microglia M1-like polarization","volume":"260","author":"Tong","year":"2025","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.metabol.2026.156748_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2024.102106","article-title":"Adipose tissue-derived mesenchymal stem cells promote the vascularization of pancreatic islets transplanted into decellularized pancreatic skeletons","volume":"86","author":"Zacharovova","year":"2024","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.metabol.2026.156748_bb0290","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13287-024-03974-z","article-title":"Human mesenchymal stem\/stromal cell based-therapy in diabetes mellitus: experimental and clinical perspectives","volume":"15","author":"Zeinhom","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.metabol.2026.156748_bb0295","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s11033-025-11133-7","article-title":"Mesenchymal stem cell therapy for type 2 diabetes: mechanisms, clinical evidence, and future directions","volume":"52","author":"Zarei","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.metabol.2026.156748_bb0300","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13098-025-01619-6","article-title":"Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Kashbour","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2026.156748_bb0305","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/epi-2023-0302","article-title":"Applicability of mesenchymal stem cell-derived exosomes as a cell-free miRNA therapy and epigenetic modifiers for diabetes","volume":"15","author":"Sharma","year":"2023","journal-title":"Epigenomics"},{"key":"10.1016\/j.metabol.2026.156748_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114356","article-title":"Enhancers of mesenchymal stem cell stemness and therapeutic potency","volume":"162","author":"Al-Azab","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2026.156748_bb0315","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biochi.2025.07.011","article-title":"The promise of cell-based therapies in diabetes: a review of mesenchymal stem cell applications and trials","volume":"237","author":"Li","year":"2025","journal-title":"Biochimie"},{"key":"10.1016\/j.metabol.2026.156748_bb0320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12015-025-10993-7","article-title":"Stem cell based regenerative applications for the Management of Diabetes Induced Systemic Complications","volume":"22","author":"Saeed","year":"2026","journal-title":"Stem Cell Rev Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526002611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:40:47Z","timestamp":1791520847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526002611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":64,"alternative-id":["S0026049526002611"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156748","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal stem cell therapy for diabetes: clinical evidence, emerging strategies, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156748"}}